BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22291938)

  • 1. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.
    Yan W; Zhang W; You G; Bao Z; Wang Y; Liu Y; Kang C; You Y; Wang L; Jiang T
    PLoS One; 2012; 7(1):e30339. PubMed ID: 22291938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
    Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
    Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
    AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
    Yan W; Liu Y; Yang P; Wang Z; You Y; Jiang T
    Oncotarget; 2015 May; 6(13):11676-82. PubMed ID: 25869098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.
    Li R; Li H; Yan W; Yang P; Bao Z; Zhang C; Jiang T; You Y
    Oncotarget; 2015 Mar; 6(9):7318-24. PubMed ID: 25821160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients.
    Dai Y; Ning X; Han G; Li W
    Mol Neurobiol; 2016 Apr; 53(3):1501-1508. PubMed ID: 25650121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.
    Ha SY; Kang SY; Do IG; Suh YL
    J Neurooncol; 2013 May; 112(3):439-48. PubMed ID: 23412777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
    Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
    Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.
    Reifenberger G; Weber RG; Riehmer V; Kaulich K; Willscher E; Wirth H; Gietzelt J; Hentschel B; Westphal M; Simon M; Schackert G; Schramm J; Matschke J; Sabel MC; Gramatzki D; Felsberg J; Hartmann C; Steinbach JP; Schlegel U; Wick W; Radlwimmer B; Pietsch T; Tonn JC; von Deimling A; Binder H; Weller M; Loeffler M;
    Int J Cancer; 2014 Oct; 135(8):1822-31. PubMed ID: 24615357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
    Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
    Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH1 mutation of gliomas with long-term survival analysis.
    Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
    Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
    Paldor I; Drummond KJ; Kaye AH
    J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.